The operating model for clinical research is shifting. Protocols are becoming more complex — more endpoints, more procedures, more oversight. In tandem, clinical research site networks and multi-site organizations are scaling rapidly, expanding across more studies, more sites, and more complex portfolios. But execution hasn’t kept pace.
While trial complexity has accelerated, operational visibility has not.
For sponsors and CROs, the result is increasing difficulty identifying performance variability across sites in real time. By the time issues surface through monitoring or reporting, the underlying execution has already occurred, limiting the ability to intervene early or make timely decisions.
Many clinical trials are still run on an operating model designed for a different era – one built on paper-based, manual, and fragmented workflows, with visibility that comes only after the fact.
This is more than a data problem. It’s an operating model problem. And increasingly, the organizations pulling ahead are starting in a different place: At the point of data capture, using eSource as the foundation of execution. We’ll examine why building an enterprise operating model for clinical trials starts with eSource.
The Data Reality: Complexity Is the New Baseline
The structure of clinical trials has fundamentally changed over the past decade. Data from the Tufts Center for the Study of Drug Development and broader industry analyses show:
- The number of endpoints in clinical trials has nearly doubled over the past decade
- The number of procedures per protocol has increased by more than 40%
- Phase II and III trials have seen a 67% increase in procedures over time
- Data collected in Phase III trials has increased by over 280%
- Data points collected per Phase III trial have grown nearly sixfold over the past decade — from 929,000 in 2012 to 5.9 million today, growing at 11% annually
This expansion reflects progress:
- More ambitious scientific questions
- Greater regulatory scrutiny
- Increased demand for evidence across patient populations
However, this growth in complexity has consequences. As protocol complexity rises, site burden increases in parallel, leading to:
- Higher rates of protocol deviations
- Increased amendments
- Longer study timelines
Delays carry measurable financial impact. Estimates suggest clinical trial delays can cost sponsors up to $800,000 per day, with even greater downstream implications for high-value therapies.
The Limitations of the Traditional Model of Site-based Data Capture
Despite this complexity in clinical trial management, many organizations still rely on:
- Separate systems for managing, tracking, and reporting on study activity
- Paper or hybrid source documentation
- Manual transcription from visit to EDC
- Post-visit validation and monitoring
While much attention is placed on trial design and analysis, the most persistent inefficiencies occur elsewhere: In site-based execution.
Clinical trial data does not move linearly from patient to regulator. It passes through multiple transformations:
- Captured during the visit
- Recorded or transcribed into EDC
- Reviewed during monitoring
- Cleaned and validated
- Aggregated across sites and studies
- Analyzed for safety and efficacy signals
- Prepared for regulatory submission
- Reviewed by regulators
Each step introduces latency.
According to the U.S. Department of Health and Human Services, increasingly complex data collection, particularly through detailed case report forms, can significantly increase monitoring costs.
At the site level, this manifests as:
- Repeated handling of the same data
- Delayed identification of inconsistencies
- Increased reliance on retrospective monitoring
At scale, this latency compounds across studies and sites, creating delays not just at the operational level, but at the portfolio level for sponsors. Slower access to clean data directly impacts decision timelines, from site performance evaluation to dose escalation, cohort expansion, and go/no-go decisions.
This creates what can be described as an “execution gap”: the space between what is designed in the protocol and what actually happens at the site. Within that gap:
- Data is touched multiple times
- Errors are introduced and discovered later
- Visibility is delayed across stakeholders
The downstream impact on sponsors and CROs is significant, leading to slower visibility into execution, delayed operational insight, and reduced ability to manage performance proactively across a growing network of studies and locations.
As trials scale across sites and geographies, this gap becomes increasingly difficult to control. Industry observations consistently show that:
- Duplicate data entry and reconciliation can account for significant portions of coordinator time
- Monitoring activities can represent one of the largest operational cost centers
- Data queries often originate from inconsistencies introduced during manual workflows
This isn’t just inefficient. It’s structurally limiting.
Reframing the Operating Model: Start With eSource
To operate at an enterprise level, organizations must shift their operating model, starting at the point of data capture. eSource (electronic source) represents this shift. Essentially, eSource transforms the protocol into a controlled, enforceable process. Rather than documenting the visit after the fact, eSource enables:
- Protocol-driven workflows embedded directly into the visit
- Structured data capture at the point of care meeting ALCOA+ standards
- Immediate validation of data against protocol requirements
- Real-time availability of data for downstream systems
This does not only improve site execution. It fundamentally changes how sponsors and CROs interact with trial data, shifting from periodic review to continuous visibility.
When execution is structured at the source, the impact extends across the operating model.
For Sites
- Integration with other systems such as CTMS and eISF that drive cross functional workflows and robust performance analytics
- Coordinators spend less time on data cleaning and reconciliation
- Consistent execution across a network with standardized eSource
- Lower FDA audit risk and real-time audit readiness
- Easier expansion across multiple sites and studies
- Enhanced investigator oversight and staff visibility of time-driven tasks with user-tagging and external notifications
- Faster response and resolution to queries via a remote monitoring portal, supported by a complete audit trail
For Sponsors & CROs
- Faster access to high-quality data
- Reduced monitoring costs through remote oversight and cleaner first-time data
- Improved ability to detect risk and variability across sites
- Complex trial designs are assisted by protocol-driven form logic, guiding accurate and timely study data collection
- Reduced regulatory risk and complete user accountability of regulatory compliance
- Greater visibility into site performance
In aggregate, leveraging a purpose-built solution like RealTime-eSource, these improvements translate into faster study execution, lower operational burden, and more predictable performance.
Final Thoughts: eSource, Aligning with the FDA’s Vision of Real-time Clinical Trials
Regulatory momentum is increasingly aligned with this direction. The U.S. Food and Drug Administration has signaled a move toward real-time clinical trials, where data is observed continuously and decisions are made earlier in the development process.
However, real-time visibility cannot be layered on top of delayed execution. It requires a purpose-built eClinical solution like RealTime-eSource, where data is captured at the moment of care, execution is structured around the protocol, and clean, reliable data is available in real time.
In other words: Real-time trials require real-time execution
In other words: real-time trials require real-time execution, where data is captured and structured at the moment of care, during the visit, and workflows follow the protocol as it happens, rather than completed and verified after the fact.
Organizations that continue to rely on fragmented, manual, or paper-based workflows will face increasing constraints as complexity grows, both at the site level and across sponsor portfolios.
For sites, this means operational strain. For sponsors, it means delayed insight, increased cost, slower decisions, and longer cycle times.
Those that invest in structured, real-time data capture will be positioned to operate with greater precision, respond faster to emerging signals, and meet the expectations of a rapidly evolving regulatory landscape. Because in modern clinical research, you cannot build an enterprise operating model on delayed data. You have to build it at the source.
At RealTime, we’ve built our platform around this exact principle, enabling sites, sponsors, and CROs to capture, structure, and access data in real time clinical trials, when it matters most.
Read More: eSource vs. Traditional Paper-Based Methods in Clinical Trials
Read More: How eSource Turns Clinical Trial Capacity into Revenue Growth
Read More: Negotiating Sponsor Reimbursement for Site-based Technology – A Guide for Clinical Research Sites
FAQ: Building an Enterprise Clinical Trial Operating Model with eSource
What is eSource in clinical trials?
eSource (electronic source) refers to the direct capture of clinical trial data in a digital system at the point of care, during the patient visit. Instead of recording data on paper and transcribing it later, eSource enables real-time, structured data capture aligned with the study protocol.
How does eSource improve clinical trial workflows?
eSource improves clinical trial workflows by enforcing the protocol, reducing manual transcription, and enabling real-time validation of data. This streamlines execution at the site level and provides immediate visibility into study activity for sponsors and CROs.
Why are traditional paper-based workflows a problem in clinical trials?
Paper-based and hybrid workflows introduce delays because data must be recorded, transcribed, and validated after the visit. This creates an “execution gap” where errors are introduced, visibility is delayed, and monitoring becomes reactive rather than proactive.
What is the “execution gap” in clinical trials?
The execution gap is the difference between what is defined in the protocol and what actually happens at the site during study visits. It occurs when data is captured manually, re-entered across systems, and validated later—leading to delays, inconsistencies, and limited real-time visibility.
How does eSource support remote monitoring?
By making data available in near real time, RealTime eSource enables remote monitoring and risk-based oversight. Sponsors and CROs can review study data continuously rather than waiting for on-site visits, helping reduce monitoring costs and improve issue detection earlier in the process.
How does eSource help sponsors and CROs?
RealTime eSource provides sponsors and CROs with faster access to high-quality data, improving visibility across sites and studies. This enables earlier identification of risk, reduces variability in site performance, and supports faster decision-making across the clinical trial portfolio.
How does eSource improve data quality in clinical trials?
RealTime eSource improves data quality by validating data at the point of capture using protocol-driven workflows and edit checks. This reduces transcription errors and minimizes downstream data queries.
What is an enterprise operating model for clinical trials?
An enterprise operating model for clinical trials is a structured approach to managing study execution across sites, systems, and stakeholders. It requires standardized workflows, real-time visibility, and scalable infrastructure to support increasingly complex trials.
Why should an enterprise operating model start with eSource?
An enterprise operating model, especially for site networks and growing multi-sites, depends on timely, accurate data. eSource ensures data is captured in real time at the point of care, creating a reliable foundation for monitoring, reporting, and decision-making across the organization.
How does eSource support real-time clinical trials?
Real-time clinical trials require continuous access to accurate data. eSource enables this by capturing and structuring data during the visit, making it immediately available for analysis and oversight—aligned with the direction signaled by the U.S. Food and Drug Administration.
What are the benefits of eSource for site networks?
For clinical research sites and networks, RealTime eSource:
- Standardizes study execution
- Lower FDA audit risk
- Improves audit readiness
- Reduces coordinator workload
- Increased coordinator capacity to handle more studies
- Enables scaling across more studies and sites
What are the benefits of eSource for sponsors?
For sponsors and CROs, RealTime eSource:
- Accelerates access to clean data
- Reduces monitoring costs
- Improves site performance visibility
- Enables faster go/no-go decisions